ERBB2 and gastric cancer: DESTINY-Gastric01 (NCT03329690, phase 2) evaluates trastuzumab deruxtecan (DS-8201a) in patients with HER2-positive tumors (non-resectable or metastatic GEJ adenocarcinoma GC versus physician’s choice (paclitaxel or irinotecan monotherapy or SOC), with the experimental arm having a higher ORR [109]).